CD5 is also occasionally expressed on B-cell neoplasms, but its clinicopathological significance in low-grade B-cell non-Hodgkin's lymphomas (NHL), notably MALT lymphomas, remains obscure [7]. This evidence concerns the gene CD5 and B-cell neoplasm.